May 29, 2026

Partnership Between Heidelberg and Harvard: Implementation of Initial Projects Begins

Partnership Between Heidelberg and Harvard: Implementation of Initial Projects Begins

23 joint initiatives selected for funding – focus on long-term cooperation

The strategic partnership between Heidelberg University and Harvard University is now seeing the launch of the first joint projects by researchers from the two institutions. In August 2025, their respective leading representatives had signed a Memorandum of Understanding in order to broaden the existing cooperation. 23 initiatives were chosen for funding in the first selection procedure. They are intended to deepen established cooperation arrangements through joint research, to build on transatlantic networks and drive forward projects with great scientific momentum. Project funding started on 1 April 2026.

“The partnership-related projects form the core of the scientific collaboration between our universities. They aim to establish lasting research cooperation agreements, promote innovative, interdisciplinary approaches and strengthen the chances of early-career researchers,” underlines Prof. Dr Frauke Melchior, Rector of Heidelberg University. This alliance will seek to foster broad and meaningful collaborations between the two institutions. “The partnership between our University of Excellence in Heidelberg and the renowned Harvard University is evolving from a strategic agreement into a concrete and effective platform for cutting-edge international research – exactly as we envisioned with our state initiative, ‘Global Partnership in Science’, as a symbol of international and independent scientific collaboration. This close cooperation at the highest level also demonstrates that Baden-Württemberg is an outstanding hub for science and research with global appeal,” adds science minister Petra Olschowski.

30 project applications were submitted in the partnership’s first call for interest. In a competitive procedure, a joint commission of the two universities selected 23 projects for funding. Seven projects in the program line “Strategic Partnership Grant” aim to expand institutional cooperation agreements. The program line “Explorer Seed Fund” will finance 16 projects with immediate scientific momentum. In all, around 220 academics are involved – mainly in early career phases. 130 of them pursue their research at Heidelberg University and 90 are members of Harvard University. The first visits by United States researchers are planned for the 2026 summer semester, while most of the visiting researchers are expected in Heidelberg during the 2026/2027 winter semester. 

The 23 projects now being funded cover a wide range of disciplines at Heidelberg University. In all, applications were approved from nine different faculties. Medicine is a particular focus with nine successful applications. Here some of the initiatives build on longstanding partnerships – for example in the area of Global Health. The projects are planned to run for up to 24 months. A further call for applications will follow in the near future.

The strategic partnership has a time-honored foundation: Harvard University has for decades been the U.S. university with which Heidelberg University maintains the most extensive relations of active cooperation. It was based on this historical cooperation that the leading bodies of the two universities resolved to enter into strategic partnership in August 2025. The state of Baden-Württemberg is supporting the partnership in the context of the science ministry’s “Global Partnership in Science” activities and providing a total of ten million euros in funding.

Further Information

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp